According to CRI’s market research, the sales value of Insulin Glargine has shown an upward trend from 2016 to 2020 in China, reaching CNY960.49 million in 2020. Sales growth in 2020 has slowed down compared to previous years. The main reason is that the COVID-19 epidemic has impacted the hospital’s overall diagnosis and treatment business. The CAGR of the sales value of Insulin Glargine in the Chinese market is 5.45% from 2016 to 2020.

CRI predicts that from 2021 to 2025, the sales of Insulin Glargine in China will have a recovery growth with the improvement of the epidemic and the normal operation of the hospital’s overall diagnosis and treatment business. In addition, its sales will also increase due to market expansion. The number of diabetic patients in China has ranked the first in the world, and there is a great demand for diabetes treatment drugs. Insulin Glargine belongs to the third generation of insulin. Compared with other types of insulin, third-generation insulin has greater advantages in terms of onset time, peak performance, and duration of action, indicating that the Insulin Glargine market has room for growth in China. In addition, the key patent of Insulin Glargine expired in 2015, and more generic drugs will appear in the Insulin Glargine market in the future. Therefore, the price of Insulin Glargine is expected to continue to fall, driving sales volume to increase sales.

Topics Covered:
-The impact of COVID-19 on China’s Insulin Glargine market
– Sales value of China’s Insulin Glargine 2016-2020
– Competitive landscape of China’s Insulin Glargine market
– Prices of Insulin Glargine in China
– Prices of Insulin Glargine in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Insulin Glargine market
– Prospect of China’s Insulin Glargine market from 2021 to 2025

The post Investigation Report on China’s Insulin Glargine Market 2021-2025 first appeared on CRI Report.

According to CRI’s market research, Sitagliptin’s sales in the Chinese market have increased year by year. Sitagliptin was included in the medical insurance reimbursement catalog in 2017, so the sales value of China’s Sitagliptin growth in 2018 was the most obvious, rising from CNY116.98 million in 2017 to CNY233.37 million in 2018, with an annual growth rate of 99.50%. In 2020, due to the impact of the COVID-19 epidemic, the growth rate of Sitagliptin sales fell, but the sale value of Sitagliptin reached CNY389.69 million. The CAGR of Sitagliptin’s sales value in the Chinese market from 2016 to 2020 is 47.44%.

CRI expects that its sales will continue to grow from 2021 to 2025 as the effective alleviation of the COVID-19 epidemic. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. successfully won the first domestic imitation of Sitagliptin after the approval in 2020 and became the fourth domestically-made DPP-4 inhibitor drug. The patent of Sitagliptin will expire in 2022. In the future, its manufacturers will gradually increase, the market will continue to expand, and prices will have a downward trend, which will lead to an increase in Sitagliptin sales and sales volume. Compared with traditional hypoglycemic drugs, sitagliptin does not increase the risk of hypoglycemia and affects weight Neutrality, good cardiovascular safety, and other advantages. Based on these advantages, Sitagliptin ranks first in the DPP-4 inhibitor market. In addition, the huge patient population. The huge patient population will enable the Sitagliptin market to continue to expand. Therefore, Sitagliptin sales will continue to grow from 2021 to 2025 as the market expands.

Topics Covered:
-The impact of COVID-19 on China’s Sitagliptin market
– Sales value of China’s Sitagliptin 2016-2020
– Competitive landscape of China’s Sitagliptin market
– Prices of Sitagliptin in China
– Prices of Sitagliptin in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Sitagliptin market
– Prospect of China’s Sitagliptin market from 2021 to 2025

The post Investigation Report on China’s Sitagliptin Market 2021-2025 first appeared on CRI Report.